<DOC>
	<DOCNO>NCT00206128</DOCNO>
	<brief_summary>The purpose study determine efficacy sustain release ( SR ) formulation quetiapine ( Seroquel ) inferior immediate release ( IR ) formulation . PLEASE NOTE : Seroquel SR Seroquel XR refer formulation . The SR designation change XR consultation FDA .</brief_summary>
	<brief_title>Immediate Release ( IR ) Sustained Release ( SR ) Switching Study : Study Switching From IR Seroquel SR Seroquel Outpatients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>A stable dose quetiapine IR 300 800 mg/day within 4 week prior enrolment visit ( Visit 1 ) judge investigator . Female patient childbearing potential must negative serum pregnancy test enrolment willing use reliable method birth control , ie , barrier method , oral contraceptive , implant , dermal contraception , longterm injectable contraceptive , intrauterine device , tubal ligation study . Able understand comply requirement study , judge investigator . Meeting criterion ( schizophrenia ) Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) Axis I diagnosis , concomitant organic mental disorder mental retardation . Patients substance abuse dependence , define DSMIV , full remission . A urine drug screen test perform . The investigator evaluate result along medical history determine patient meet DSMIV criterion substance abuse dependence . Risk transmit human immunodeficiency virus ( HIV ) hepatitis B , via blood body fluid , judge investigator . Patients , opinion investigator , pose imminent risk suicide danger self others .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>